Royal Fund Management’s Atossa Therapeutics ATOS Stock Holding History

Royal Fund Management’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,000	Closed	-$31K	–	192
2021 Q1	$31K	Buy	+1,000	New	+$36.5K	0.01%	182

Other funds holding ATOS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Royal Fund Management's ATOS Position: Q2 2021 in Review

Royal Fund Management sold out of Atossa Therapeutics (ATOS) in Q2 2021, closing a stake of 1,000 shares — an estimated $31K sold.

Royal Fund Management first reported a position in ATOS in Q1 2021 and held it in 1 quarter. The position peaked at $31K in Q1 2021. 86 funds tracked by Wall St. Rank hold ATOS as of Q2 2021.

Royal Fund Management reported no remaining Atossa Therapeutics position as of Q2 2021 after selling out during the quarter.
Royal Fund Management sold 1,000 Atossa Therapeutics shares in Q2 2021, an estimated $31K.
Royal Fund Management first reported a position in Atossa Therapeutics in Q1 2021 and held it in 1 quarter.
Royal Fund Management's Atossa Therapeutics position peaked at $31K in Q1 2021.
86 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2021.

Based on Royal Fund Management's 13F filing for Q2 2021, filed 26 Jul 2021.